title: Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide).
abstract: Preclinical studies established [125I]-N-(2-diethylaminoethyl) 4-iodobenzamide (BZA) as a potential radiopharmaceutical in the management of patients with malignant melanoma. External detection of both murine and human melanotic melanomas was possible after intravenous injection of 125I-BZA in tumor-bearing mice. This article reports a Phase II clinical trial evaluating 123I-BZA as an imaging agent of primary melanomas and metastases. A total of 110 patients with a history of melanoma were investigated in two nuclear medicine departments. Subjects were imaged from 20 to 24 hr after the intravenous injection of 3.5 mCi (130 MBq) of 123I-BZA. After injection, no short-term or long-term side effects were noted. Calculated on a lesion-site basis, diagnostic sensitivity was 81%, accuracy was 87% and specificity was 100%. The melanoma nature of previously occult lesions was confirmed by clinical criteria and/or additional investigations in follow-up studies. The scintigraphies were normal in 44 patients in clinical remission after treatment of malignant melanoma and in seven patients with nonmelanoma disease. No false positive results were observed. Iodine-123-BZA scintigraphy appears to be a safe and useful agent for the detection and follow-up of patients with malignant melanoma. BZA also allowed the detection of unsuspected lesions and the evaluation of the results of various therapeutic procedures such as surgery, chemotherapy, immunobiology, biological therapy or radiotherapy.
authors.affiliation: INSERM U 71, Clermont-Ferrand, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Michelot
authors.forename: M F
authors.initials: MF
authors.lastname: Moreau
authors.forename: A J
authors.initials: AJ
authors.lastname: Veyre
authors.forename: J F
authors.initials: JF
authors.lastname: Bonafous
authors.forename: F J
authors.initials: FJ
authors.lastname: Bacin
authors.forename: J C
authors.initials: JC
authors.lastname: Madelmont
authors.forename: F
authors.initials: F
authors.lastname: Bussiere
authors.forename: P A
authors.initials: PA
authors.lastname: Souteyrand
authors.forename: L P
authors.initials: LP
authors.lastname: Mauclaire
authors.forename: F M
authors.initials: FM
authors.lastname: Chossat
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011877:Radionuclide Imaging; D012680:Sensitivity and Specificity
chemical_list: D001549:Benzamides; D007457:Iodine Radioisotopes; C066918:N-(2-(diethylamino)ethyl)-4-iodobenzamide